Literature DB >> 1423224

t(9;11)(p22;q23) translocation in blastic phase of chronic myeloid leukemia.

N Dastugue1, E Duchayne, F Huguet, C Demur, H Plaisancie, P Calvas, G Bourrouillou, J Pris, P Colombies.   

Abstract

A patient with chronic myeloid leukemia showed clonal karyotypic evolution, with the appearance of an i(17q) and t(9;11)(p22;q23). This case sheds light upon leukemogenic events related to t(9;11)(p22;q23). The presence of t(9;22) and t(9;11) in the same clone showed that t(9;11) may affect a pluripotent stem cell, thus accounting for t(9;11) in both lymphoid and monocytic leukemias. In this patient, t(9;11) could not be related to a prior cytotoxic exposure and was instead the result of natural evolution of chronic myeloid leukemia. Furthermore, this led us to assume that the phenotype of blast cells may be determined by a chromosome abnormality. A phenotypic conversion from myeloblastic to undifferentiated morphologic aspect was observed when t(9;11) was detected, suggesting that t(9;11) may have induced a loss in differentiation of blast cells affected by this change. This assumption is in agreement with the putative presence of genes activated in pluripotent progenitors by 11q23 rearrangements.

Entities:  

Mesh:

Year:  1992        PMID: 1423224     DOI: 10.1016/0165-4608(92)90061-c

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  An unusual translocation, t(1;11)(q21;q23), in a case of chronic myeloid leukemia with a cryptic Philadelphia chromosome.

Authors:  Leandro Germán Gutiérrez; María Fernanda Noriega; Alejandro Laudicina; Mariana Quatrin; Raquel María Bengió; Irene Larripa
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

2.  Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.

Authors:  Wei Wang; Guilin Tang; Jorge E Cortes; Hui Liu; Di Ai; C Cameron Yin; Shaoying Li; Joseph D Khoury; Carlos Bueso-Ramos; L Jeffrey Medeiros; Shimin Hu
Journal:  J Hematol Oncol       Date:  2015-04-08       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.